Fabrice André, MD, PhD, received his MD in 2002, and a PhD in Biotechnology from Paris University in 2005. He is a medical oncologist and Director of Research at Institut Gustave Roussy in Villejuif, France, specializing in breast cancer and Professor of Medicine at the Paris-Saclay University.

His research work in the field of biomarkers and personalized therapies focuses on biomarker discovery, development of targeted agents and implementation of personalized medicine. His team includes 80 people working on basic sciences, bioinformatics, biotechnologies and clinical research. He is also leading phase I-III trials testing targeted agents in the field of breast cancer and large national trials testing implementation of high throughput technologies in the health care system.

Professor André has published more than 300 peer reviewed papers, including papers in Nature, the New England Journal of Medicine, Lancet, Nature Medicine.
He is chairman of the biomarker group at UNICANCER (French cooperative group) and was a member of several scientific committees for international meetings, including SABCS, AACR, ECCO, ESMO, and IMPAKT.

Professor André is currently President-Elect of the European Society for Medical Oncology (ESMO). He has been a member of the Annals of Oncology Editorial Board (2010-2013), Associate Editor since 2014 and Editor-in-Chief 2017-2023.